STOCK TITAN
  1. Home
  2. Sec-filings
  3. INSP
  4. [Form 4] Inspire Medical Systems, Inc. Insider Trading Activity

INSP director reports 221-share equity award in lieu of cash fees

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Inspire Medical Systems (INSP) director Casey M. Tansey reported an equity award. On 10/14/2025, Tansey acquired 221 shares of common stock at $78.84 per share, received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy.

Following this transaction, Tansey beneficially owned 22,235 shares directly. Additional indirect holdings reported include 500 shares held by The Kimberly Tansey Irrevocable Trust and 500 shares held by The Kylie Tansey Irrevocable Trust.

Positive

  • None.

Negative

  • None.
Insider Tansey Casey M
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 221 $78.84 $17K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 22,235 shares (Direct); Common Stock — 500 shares (Indirect, By Family Trust)
Footnotes (1)
  1. Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Securities held by The Kimberly Tansey Irrevocable Trust. Securities held by The Kylie Tansey Irrevocable Trust.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tansey Casey M
(Last) (First) (Middle)
C/O INSPIRE MEDICAL SYSTEMS, INC.
5500 WAYZATA BLVD., SUITE 1600
(Street)
GOLDEN VALLEY MN 55416
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Inspire Medical Systems, Inc. [ INSP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/14/2025 A 221(1) A $78.84 22,235 D
Common Stock 500 I By Family Trust(2)
Common Stock 500 I By Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.
2. Securities held by The Kimberly Tansey Irrevocable Trust.
3. Securities held by The Kylie Tansey Irrevocable Trust.
/s/ Bryan Phillips, Attorney-in-Fact for Casey M. Tansey 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did INSP director Casey M. Tansey report on Form 4?

Tansey reported acquiring 221 shares of common stock on 10/14/2025 at $78.84 per share, received in lieu of cash fees.

How many INSP shares does Casey M. Tansey own after the transaction?

Tansey reported 22,235 shares held directly after the transaction.

Were there any indirect holdings disclosed for INSP?

Yes. The filing lists 500 shares held by The Kimberly Tansey Irrevocable Trust and 500 shares held by The Kylie Tansey Irrevocable Trust.

What was the price per share for the INSP shares reported?

The reported price per share was $78.84.

What was the nature of consideration for the acquired shares?

The shares were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy.

Does this filing indicate a trade under a Rule 10b5-1 plan?

The excerpt does not indicate that the Rule 10b5-1 box was checked.